SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is drawing attention as traders react to projected Democratic gains in the midterms, with concerns that tighter AI and data-center rules could weigh on large-cap technology stocks. The community is divided between expecting further downside and viewing the selloff as an overreaction or dip-buying opportunity.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Expected Democratic gains in the midterms dominate discussion, with traders viewing a potential sweep as a political setback for Trump and a negative for Trump Media; many express bearish sentiment, while some dispute the outlook. The news also links DJTs decline to markets pricing in Democratic gains.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

Traders are focused on election results and the prospect that Democratic gains could bring greater scrutiny of Musks companies, government contracts, and data-center expansion; those concerns are speculation rather than confirmed policy changes. The debate is polarized, with bearish posts anticipating pressure on SpaceX and its Tesla-merger prospects, while bulls argue its business and long-term technology potential remain intact.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Midterm-election uncertainty and speculation that Democratic gains could mean tighter AI or data-center rules dominate NVDA discussion, with traders divided over whether that threatens chip demand or is already priced in. Strong AMD results and a broader semiconductor rebound have also supported a more optimistic view of the AI buildout.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMDs quarterly beat and stronger outlook, fueled by AI and data-center demand, prompted a sharp after-hours rally. Traders are debating whether the gains can hold amid broader market weakness and election-related concerns about data-center restrictions, as well as questions about valuation and cash flow.

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,105,365. The last known price of Bitcoin is 76,984.36452344 USD and is up -0.00 over the last 24 hours. It is currently trading on 12773 active market(s) with $23,094,171,945.49 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoin discussion is dominated by U.S. midterm-election uncertainty, with traders debating whether projected Democratic gains could hurt crypto through regulation and broader market weakness or instead clear uncertainty and support a rally. The community is sharply divided between bearish calls and dip-buying optimism, alongside debate over whether recent support will hold.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Teslas weakness is being tied by traders to perceived Democratic gains in midterm races and concerns that Musk could face greater scrutiny or lose political support, with a possible TeslaSpaceX merger also in focus. Views are divided: bears see political and merger risks weighing on the stock, while some traders point to potential EV-policy benefits or expect a rebound.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is rebounding amid a volatile semiconductor selloff that traders linked to fears a Democratic sweep could bring tighter limits on AI data-center growth. Bulls point to strong AMD and SMCI results and continuing AI demand, while bears remain concerned about policy uncertainty and a possible AI bubble; traders also warn that the funds 3x leverage can amplify losses and decay.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Midterm-election uncertainty has dominated Micron chatter, with traders speculating that a Democratic sweep could bring data-center restrictions and pressure AI-linked stocks; others argue the AI buildout will continue regardless. Strong AMD results and expectations of persistent memory shortages have fueled bullish calls, but the community remains divided amid sharp swings and concerns about fading rallies.

Cipher Digital, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Digital Inc.

Cipher Digitals Q3 update is driving debate: traders are weighing the revenue miss against its first HPC lease revenue and expanded long-term data-center lease, while the sharp rebound has drawn bullish calls on its AI-infrastructure pipeline. Skeptics remain concerned about buildout costs, financing and execution as the company shifts from bitcoin mining to data-center leasing.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

GRCE Investors Have Opportunity to Join Grace Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

GRCE Investors Have Opportunity to Join Grace Therapeutics, Inc. Fraud Investigation with the Schall Law Firm GRCE Investors Have Opportunity to Join Grace Therapeutics, Inc. Fraud Investigation with the Schall Law Firm PR Newswire LOS ANGELES, June 8, 2026 LOS ANGELES, June 8, 2026 /PRNewswire...

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grace Therapeutics, Inc. (Grace or the Company) (NASDAQ: GRCE) for violations of the securities laws.The investigation focuses on whether the Company issued false...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Grace Therapeutics, Inc. - GRCE

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Grace Therapeutics, Inc. - GRCE INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Grace...

GRCE Stock On Track For Worst Week In 5.5 Years —  What’s Driving The Selloff?

Equity

Earlier this week, the FDA refused to approve Grace Therapeutics’s experimental drug for the treatment of a severe form of acute brain injury.


GRCE Stock Plunges 45% After FDA Rejects Brain Injury Drug — Company Says Concerns Are Fixable

Grace Therapeutics was seeking FDA approval for GTx-104 in the treatment of patients with aneurysmal subarachnoid hemorrhage. 


GRCE Stock In Spotlight Ahead Of FDA Verdict On Brain Bleed Drug This Week 

The FDA set a Prescription Drug User Fee Act target action date of April 23 to rule on GTx-104, a potential treatment for patients with aneurysmal subarachnoid hemorrhage.

Short Interest in Grace Therapeutics, Inc. (NASDAQ:GRCE) Grows By 300.8%

Grace Therapeutics, Inc. (NASDAQ:GRCE - Get Free Report) was the recipient of a significant increase in short interest in the month of March. As of March 13th, there was short interest totaling...

Grace Therapeutics, Inc. (NASDAQ:GRCE) Short Interest Update

Grace Therapeutics, Inc. (NASDAQ:GRCE - Get Free Report) was the recipient of a large increase in short interest in the month of February. As of February 27th, there was short interest totaling...

Grace Therapeutics, Inc. (NASDAQ:GRCE - Get Free Report) was the target of a significant growth in short interest during the month of February. As of February 13th, there was short interest totaling...

Grace Therapeutics (NASDAQ:GRCE) Announces Earnings Results

Grace Therapeutics (NASDAQ:GRCE - Get Free Report) posted its earnings results on Thursday. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus...

Grace Therapeutics, Inc. engages in the development and commercialization of drug candidates for rare and orphan diseases. It focuses on utilizing proprietary technologies to improve the performance of currently marketed drugs. The company was founded by Henri Harland and Pierre Lemieux on February 1, 2002 and is headquartered in Princeton, NJ.

Grace Therapeutics Inc.

Bullish Sentiment

<ul class="summary-bullets"><li>Grace was seeking FDA approval for GTx-104 in the treatment of patients with aneurysmal subarachnoid hemorrhage.</li><li>However, the FDA issued a letter to it on Thursday, citing issues in the Chemistry, Manufacturing, and Controls (CMC) and Non-Clinical sections of its application.</li><li>Analysts from Craig-Hallum and TD Cowen slashed price targets on the stock on Friday following the FDA decision.</li></ul><p>Shares of Grace Therapeutics (GRCE) are on track for their worst week since Sept. 2020, after the U.S. Food and Drug Administration refused to approve its experimental drug for the treatment of a severe form of acute brain injury, sparking price target cuts.</p><p>Shares of the company are down 49% this week, if losses hold.</p><h2 class="st-heading-2">FDA Rejection</h2><p>Grace was seeking FDA approval for GTx-104 in the treatment of patients with aneurysmal subarachnoid hemorrhage (aSAH), or bleeding over the surface of the brain in the space between the brain and the skull as a result of a ruptured brain aneurysm.</p><p>However, the FDA <a href="https://stocktwits.com/news-articles/markets/equity/grce-stock-plunges-after-fda-rejects-brain-injury-drug-company-says-concerns-are-fixable/cZBQevVReTT">issued </a>a letter to it on Thursday, citing issues in the Chemistry, Manufacturing, and Controls (CMC) and Non-Clinical sections of its application. The agency highlighted leachables data for product packaging, non-clinical product toxicology risk assessments, and product manufacturing deficiencies at the company’s contract manufacturing organization, it said.</p><h2 class="st-heading-2">Wall Street Weighs In</h2><p>Craig-Hallum lowered the firm's price target on Grace Therapeutics to $4 from $11 and kept a ‘Buy’ rating on the shares following the announcement. The firm believes Grace has enough runway to address the deficiencies highlighted by the FDA and an application resubmission, though shares are unlikely to move higher until further visibility is provided, it said.</p><p>TD Cowen analyst Stacy Ku also lowered the firm's price target on Grace Therapeutics to $8 from $12 and kept a ‘Buy’ rating on the shares. The firm noted that GTx-104's rejection is related to CMC, with no requests for additional clinical data. Management will seek a meeting with the FDA, which should clarify resubmission timelines, the analyst said. The firm assumes a roughly 12-month delay, with potential for faster resolution.</p><h2 class="st-heading-2">Grace Chimes In</h2><p>“We are confident in the robust data package supporting our NDA (application) submission, and that the CMC issues identified by the FDA can be successfully addressed in our resubmission,” CEO Prashant Kohli said on Thursday following the receipt of the FDA letter.</p><h2 class="st-heading-2">How Did Retail Traders React?</h2><p>On Stocktwits, retail sentiment around GRCE stock stayed within ‘bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.</p><p>A Stocktwits user highlighted that the issues cited by the FDA are fixable and the stock will bounce back up.</p><p><stembedurl>https://www.stocktwits.com/h8ster/message/651317731</stembedurl></p><p>Another user dismissed the rejection and instead highlighted possible risks of dilution from capital raising initiatives.</p><p><stembedurl>https://www.stocktwits.com/Stockseeking/message/651266436</stembedurl></p><p><a href="https://stocktwits.com/symbol/GRCE">GRCE stock</a> is down 8% over the past 12 months.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/cmps-on-track-for-best-week-ever-on-fda-push-for-psychedelics/cZBhaQDReck">CMPS On Track For Best Week Ever On FDA Push For Psychedelics</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In the wake of OWL's redemption restrictions, Senator Elizabeth Warren called for tighter oversight of private credit.

Earlier this week, the FDA refused to approve Grace Therapeutics’s experimental drug for the treatment of a severe form of acute brain injury.

Vanguard Total Stock Market ETF

Republicans keep both chambers

Republicans keep the House, lose the Senate

Republicans keep the Senate, lose the House

Democrats win both chambers

Stocktwits

Stocktwits Polls

$GRCE Terrible volume. I was going to buy this morning but 7 cents spread. I don’t think we’ll see below $2 again. 🤞

Greenpa

$GRCE this is getting interesting.  Small volume, small float, high price volitility, and a pretty successful bio fund keeps buying. Maybe a buyout is in the cards.  We'll see...

deweyeggbert

$GRCE Stop-Loss-Testing. We already know this here. I do the same as Opaleye: Buying more.

cartman

$GRCE what does opaleye see that others are missing?  They keep accumulating shares in small increments, which are adding up to a sizable position.

Feed

News

Sentiment

Earnings

Fundamentals

Info

GRCE Grace Therapeutics Inc.

Fundamentals

Latest GRCE News